High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

被引:28
作者
McCullough, RM
Cantor, CR
Ding, CM
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Ctr Emerging Infect Dis, Sch Publ Hlth,Fac Med, Shatin, Hong Kong, Peoples R China
[2] Program Mol & Cellular Biol & Biochem, Boston, MA 02215 USA
[3] Ctr Adv Biotechnol, Boston, MA 02215 USA
关键词
D O I
10.1093/nar/gni098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alternative splicing is a significant contributor to transcriptome diversity, and a high-throughput experimental method to quantitatively assess predictions from expressed sequence tag and microarray analyses may help to answer questions about the extent and functional significance of these variants. Here, we describe a method for high-throughput analysis of known or suspected alternative splicing variants (ASVs) using PCR, primer extension and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Reverse-transcribed mRNA is PCR amplified with primers surrounding the site of alternative splicing, followed by a primer extension reaction designed to target sequence disparities between two or more variants. These primer extension products are assayed on a MALDI-TOF mass spectrometer and analyzed automatically. This method is high-throughput, highly accurate and reproducible, allowing for the verification of the existence of splicing variants in a variety of samples. An example given also demonstrates how this method can eliminate potential pitfalls from ordinary gel electrophoretic analysis of splicing variants where heteroduplexes formed from different variants can produce erroneous results. The new method can be used to create alternative variant profiles for cancer markers, to study complex splicing regulation, or to screen potential splicing therapies.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 41 条
[21]   Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases [J].
Nagane, M ;
Levitzki, A ;
Gazit, A ;
Cavenee, WK ;
Huang, HJS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (10) :5724-5729
[22]  
Olopade OI, 1997, CANCER J SCI AM, V3, P230
[23]   αCP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant αCP-4a, is underexpressed in lung cancer [J].
Pio, R ;
Zudaire, I ;
Pino, I ;
Castaño, Z ;
Zabalegui, N ;
Vicent, S ;
Garcia-Amigot, F ;
Odero, MD ;
Lozano, MD ;
Garcia-Foncillas, J ;
Calasanz, MJ ;
Montuenga, LM .
CANCER RESEARCH, 2004, 64 (12) :4171-4179
[24]   Expression of apoptosis-regulatory genes in lung tumour cell lines: Relationship to p53 expression and relevance to acquired drug resistance [J].
Reeve, JG ;
Xiong, J ;
Morgan, J ;
Bleehan, NM .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1193-1200
[25]   The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review [J].
Ribatti, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (03) :303-309
[26]  
Robinson CJ, 2001, J CELL SCI, V114, P853
[27]   Quantitative approach to single-nucleotide polymorphism analysis using MALDI-TOF mass spectrometry [J].
Ross, P ;
Hall, L ;
Haff, LA .
BIOTECHNIQUES, 2000, 29 (03) :620-+
[28]   SPLIT GENES AND RNA SPLICING [J].
SHARP, PA .
CELL, 1994, 77 (06) :805-815
[29]   Role of alternative splicing in generating isoform diversity among plasma membrane calcium pumps [J].
Strehler, EE ;
Zacharias, DA .
PHYSIOLOGICAL REVIEWS, 2001, 81 (01) :21-50
[30]   Aberrant messenger RNA splicing of the cytokeratin 8 in lung cancer [J].
Tojo, Y ;
Bandoh, S ;
Fujita, J ;
Kubo, A ;
Ishii, T ;
Fukunaga, Y ;
Ueda, Y ;
Yang, Y ;
Wu, F ;
Huang, CL ;
Yokomise, H ;
Ishida, T .
LUNG CANCER, 2003, 42 (02) :153-161